- Home
- CRSP vs FORM Comparison
CRSP vs FORM Comparison
Compare CRSP & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- FORM
- Stock Information
- Founded
- CRSP 2013
- FORM 1993
- Country
- CRSP Switzerland
- FORM United States
- Employees
- CRSP N/A
- FORM N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- FORM Semiconductors
- Sector
- CRSP Health Care
- FORM Technology
- Exchange
- CRSP Nasdaq
- FORM Nasdaq
- Market Cap
- CRSP 3.4B
- FORM 2.9B
- IPO Year
- CRSP 2016
- FORM N/A
- Fundamental
- Price
- CRSP $36.99
- FORM $28.64
- Analyst Decision
- CRSP Buy
- FORM Buy
- Analyst Count
- CRSP 19
- FORM 8
- Target Price
- CRSP $74.35
- FORM $48.00
- AVG Volume (30 Days)
- CRSP 1.6M
- FORM 773.5K
- Earning Date
- CRSP 05-07-2025
- FORM 04-30-2025
- Dividend Yield
- CRSP N/A
- FORM N/A
- EPS Growth
- CRSP N/A
- FORM N/A
- EPS
- CRSP N/A
- FORM 0.89
- Revenue
- CRSP $37,314,000.00
- FORM $763,599,000.00
- Revenue This Year
- CRSP $49.76
- FORM $4.29
- Revenue Next Year
- CRSP $257.28
- FORM $7.08
- P/E Ratio
- CRSP N/A
- FORM $33.39
- Revenue Growth
- CRSP N/A
- FORM 15.16
- 52 Week Low
- CRSP $36.52
- FORM $28.46
- 52 Week High
- CRSP $68.39
- FORM $63.63
- Technical
- Relative Strength Index (RSI)
- CRSP 34.31
- FORM 30.99
- Support Level
- CRSP $40.41
- FORM $30.75
- Resistance Level
- CRSP $42.72
- FORM $32.65
- Average True Range (ATR)
- CRSP 1.73
- FORM 1.20
- MACD
- CRSP -0.55
- FORM -0.03
- Stochastic Oscillator
- CRSP 0.80
- FORM 3.83
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc designs, develops, manufactures, sells, and supports semiconductor probe card products. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.